Status:
COMPLETED
mHealth Mood Management Tool (Actify) to Improve Population-Level Smoking Cessation
Lead Sponsor:
Fred Hutchinson Cancer Center
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Cigarette Smoking-Related Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This phase I trial investigates a new smartphone application (called Actify) for improving population-level smoking cessation and mood management. Actify delivers behavioral activation therapy for dep...
Detailed Description
OUTLINE: Participants are randomized to 1 of 2 arms. ARM I: Participants use Actify app for smoking cessation for 8 weeks. Participants also receive motivational messages and smoking cessation inform...
Eligibility Criteria
Inclusion
- Current smoker, averaging at least 5 cigarettes/day for the last 30 days
- Interested in quitting smoking in the next 30 days
- Experience downloading and using one or more apps on their smartphone
- Either screens negative (Patient Health Questionnaire - 9 Item \[PHQ-9\] score 0-4) for depression or screens positive for mild to moderate current depressive symptoms (PHQ-9 score 5-19)
- Willing and able to complete all study activities
- Comfortable reading and writing in English
- Have a mobile data plan and/or access to WiFi to support the use of the Actify app
- Reside in the US
- Have a smartphone either an iPhone (running iOS version 11 or higher) or an Android phone (running version 5.0 or higher)
Exclusion
- Currently receiving behavioral treatment for depression (e.g., psychotherapy)
- Current use of a depression app
- Severe depression (PHQ-9 \>= 20)
- Receiving other treatment for smoking cessation
- Previous use of the QuitGuide app
- Current or recent (within the past year) enrollment in a Fred Hutch smoking cessation study
- Employees/family of investigator or study center
- Member of the same household as another participant
- Woman who is pregnant or breastfeeding, or planning to become pregnant
- Currently incarcerated
- Is ineligible per fraud prevention protocol
Key Trial Info
Start Date :
May 9 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 12 2023
Estimated Enrollment :
242 Patients enrolled
Trial Details
Trial ID
NCT04525222
Start Date
May 9 2022
End Date
April 12 2023
Last Update
March 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States, 98109